NCT02478242

Trial to Assess the Efficacy and Safety of Nafamostat Mesilate During Continuous Renal Replacement Therapy

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Kyungpook National University Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Randomized study to evaluate the efficacy and safety of nafamostat mesilate use during continuous renal replacement therapy in acute kidney injury patients at a high risk of bleeding.

Detailed description

Patients were randomly assigned to the nafamostat mesilate (NM) group or the no anticoagulant (NA) group. In patients assigned to the NM group, NM (20mg/h) was used for maintenance anticoagulation. Whereas, in patients assigned to the NA group, normal saline (2mL/h) was infused for continuous renal replacement therapy.

Conditions

• Acute Kidney Injury

Interventions

Type	Name	Description
DRUG	Nafamostat mesilate	nafamostat mesilate use for anticoagulation
DRUG	Normal saline

Timeline

• Start date: 2010-07-01
• Primary completion: 2015-06-01
• Completion: 2015-06-01
• First posted: 2015-06-23
• Last updated: 2015-06-23